Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah ... [et al.]
Adjuvant trastuzumab has been used in human epidermal growth factor-2 (HER2) breast cancer to improve survival but with concern of cardiotoxicity. Our study is the first to review efficacy and toxicity of adjuvant trastuzumab in Malaysia. Methods: This is a retrospective cohort study on HER2 non met...
Main Authors: | Hasbullah, Harissa H (Author), Bustamam, Anita (Author), Tho, Lye Munn (Author), Phua, Vincent (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Universiti Teknologi MARA Cawangan Selangor,
2018-06.
|
Subjects: | |
Online Access: | Get fulltext View Fulltext in UiTM IR |
Similar Items
-
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
by: Sagar Sardesai, et al.
Published: (2020-11-01) -
Cardio-Oncology and the Intersection of Cancer and Cardiotoxicity
by: Richard K. Cheng, MD, MSc, et al.
Published: (2019-12-01) -
Neuroendocrine tumour of the lung: a diagnostic challenge / Nur Hidayah Bahrom ... [et al.]
by: Bahrom, Nur Hidayah, et al.
Published: (2019) -
Telemetric electrocardiography in diagnostics of cardiotoxic heart rhythm disorders and conductivity in oncologic patients
by: Nadezhda P. Lyamina, et al.
Published: (2020-09-01) -
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
by: Anthony F. Yu, MD, et al.
Published: (2020-06-01)